NASDAQ
04.09.26 | 21:55
0,540 US-Dollar
+0,39 % +0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.08. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.08. | Evogene Reports Second Quarter and First Half 2026 Financial Results | 264 | PR Newswire | Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical... ► Artikel lesen | |
| 18.08. | Evogene GAAP EPS of -$0.13 beats by $0.14, revenue of $0.35M beats by $0.02M | 1 | Seeking Alpha | ||
| 18.08. | Evogene Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 17.08. | Evogene Q2 2026 Earnings Preview | 1 | Seeking Alpha | ||
| 31.07. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| EVOGENE Aktie jetzt für 0€ handeln | |||||
| 23.07. | Evogene and ELEO to develop new oral PCSK9 inhibitors | 2 | Pharmaceutical Technology | ||
| 22.07. | Evogene; ELEO Inc.: Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases | 199 | PR Newswire | Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting... ► Artikel lesen | |
| 17.07. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 09.07. | Evogene and Tel Aviv University launch drug discovery initiative | 1 | Pharmaceutical Technology | ||
| 08.07. | Evogene partners with Tel Aviv University center on drug discovery | 1 | Investing.com | ||
| 08.07. | Evogene und Universität Tel Aviv starten Kooperation zur Wirkstoffforschung | 3 | Investing.com Deutsch | ||
| 24.06. | Evogene completes milestone in Google Cloud collaboration | 3 | Investing.com | ||
| 24.06. | Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI Toward Autonomous Small Molecule Discovery and Optimization | 271 | PR Newswire | Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines... ► Artikel lesen | |
| 11.06. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.06. | Full Transcript: Evogene Q1 2026 Earnings Call | 2 | Benzinga.com | ||
| 02.06. | Evogene schließt Phase-1-Studie für Krebsmedikament BMC128 erfolgreich ab | 8 | Investing.com Deutsch | ||
| 02.06. | Evogene completes phase 1 trial of BMC128 cancer treatment | 4 | Investing.com | ||
| 02.06. | Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica | 154 | PR Newswire | Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity
REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene")... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,55 | +0,22 % | BioNTech-Aktie: mRNA-Schock - wie groß ist der Schaden? | Die BioNTech-Aktie verliert am Freitag zeitweise zweistellig und fällt zuletzt um rund -8% auf etwa 102 US$. BioNTech und Entwicklungspartner Genentech beenden eine Phase-2-Studie mit der personalisierten... ► Artikel lesen | |
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| MODERNA | 125,24 | -0,03 % | BioNTech Aktie: Nach dem Moderna-Rausch folgt der Kater | Bei der BioNTech Aktie ging es in den vergangenen Tagen wild zu. Erst schwamm das an der NASDAQ notierte Papier auf der Welle positiver Moderna-Nachrichten nach oben und fuhr hohe Gewinne ein, dann... ► Artikel lesen | |
| STRYKER | 261,30 | +0,11 % | Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center | SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information
Stryker announced the successful completion of the first... ► Artikel lesen | |
| BIOGEN | 189,50 | -0,34 % | Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | -4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,920 | -0,19 % | 2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 | ||
| REGENERON PHARMACEUTICALS | 713,60 | +0,15 % | Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? | ||
| VIVOSIM LABS | 0,282 | +1,47 % | VivoSim Labs, Inc.: VivoSim Labs to Add Rat Liver Model to NAMkind Platform | ||
| INOVIO PHARMACEUTICALS | 1,214 | -1,06 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| CLINUVEL | 5,240 | -0,38 % | Dividendenbekanntmachungen (03.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 0,705 GBP 0,8204 EUR AEGON LTD ADR US0076CA1045 0,2455 USD 0,2118 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| INFLARX | 1,880 | -1,47 % | InflaRx im Fokus: Biotech-Pionier auf dem Weg zum medizinischen Durchbruch | ||
| INTELLIA THERAPEUTICS | 11,000 | +0,18 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,570 | -6,88 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 57,18 | -0,14 % | Ascendis Pharma: Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL (Navepegritide) | COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with... ► Artikel lesen |
Das Unternehmen EVOGENE LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,540 Euro und damit +0,39 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOGENE LTD finden Sie auf Wallstreet Online.